Latest news

• Bayer’s Nubeqa receives FDA approval to treat metastatic prostate cancer

  Bayer’s Nubeqa (darolutamide) tablets, in combination with docetaxel, have been approved by the US Food and Drug Administration (FDA) to treat adults with metastatic hormone-sensitive prostate cancer (mHSPC).

• Janssen’s Erleada improves survival in certain advanced prostate cancer patients

  Bayer/Orion’s Nubeqa (darolutamide) is a more recent competitor and it has been approved for the treatment of nmCRPC in men.

• Bayer gets EU nod for prostate cancer drug Nubeqa

  The EC has approved Nubeqa (darolutamide) as a treatment for men with non-metastatic castration-resistant prostate cancer (nmCRPC), which has become an increasingly competitive therapy area. ... With the authorisation of darolutamide in the EU,

• Givlaari, Rybelsus lead crowded CHMP recommendations

  Other notable recommendations include Bayer’s Nubeqa (darolutamide), which has been recommended for approval as a treatment for prostate cancer.

• J&J gets EMA nod for wider use of Erleada in prostate cancer

  So far, Erleada – which was also approved to treat non-metastatic castration-resistant prostate cancer (nmCRPC) a few months ahead of Xtandi and Bayer’s recently-approved competitor  Nubeqa (darolutamide) –